Johnson Matthey has announced new branding for its Fine Chemicals division.
The move is designed to unite its capabilities in chiral and catalysis technologies, opiates and narcotics and API development, life-cycle management and manufacturing.
These will be realigned under four core offerings: Custom Pharma Solutions, Controlled Substances, Catalysts and APIs & Life Cycle Management.
“This initiative aims to promote even more collaborative working across our ten global sites, thereby enabling greater advances in product development to bring significant added value to our customers’ projects,” said divisional director John Fowler.